ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition to targeted therapy, which selectively inhibits the activity of the BCR-ABL tyrosine kinase in CML cells, chemotherapy and other chemical agents are alternative approaches to reduce the number of CML cells by either killing them or inhibiting their growth and division [7].